Feedback from Related Events |
‘Thank you for organizing an excellent conference such as the “Partnerships in Clinical Trials Asia Pacific”
- Director Clinical & Regulatory, Semler Research Centre
‘I had a great time and have learned a great deal from the meeting. The agenda was very well managed’
- Vice President, Drug Development, Jiangsu Hengrui Pharmaceuticals
‘I hope your survey results support my impression that this was an excellent conference. It was very interactive and I for one certainly learned a lot.’
- Clinical Trial Outsourcing & Compliance, Compliance & Quality Management, Boehringer Ingelheim
‘Good mix of investigators, sites, pharmas and partners…led to lively discussions, good participation’
- Clinical Study Manager, Asia Pacific, Takeda Clinical Research
‘This is the best event that we’ve been to all year; we had 21 meetings, of which 19 were excellent’
- Business Development Manager, Manipal Acunova
|
Late phase trials and especially post marketing surveillance studies, are becoming more important than ever with increased emphasis from regulators. Adding on to this are prescribers’ and patients’ higher expectations in credible evidence of drug’s efficacy and safety due to raised awareness and proactive healthcare.
While late phase trials are perceived as relatively less complicated compared to earlier phases, there remain challenges arising from protocol design of post marketing research, collection of quality data, results monitoring, patient recruitment and retention, and communications between multiple parties involved.
Gathering top level experts and key opinion leaders in medical affairs, post marketing studies, clinical research and operations across the region, Late Phase Drug Development Asia2012 is the region’s most anticipated gathering for professionals involved in late phase drug development. Do not miss this meeting if you are looking into learning the best practices and latest development in the critical but ever challenging landscape of late phase studies.
Speaker Faculty consists of key personnel from Medical Affairs, Clinical Highlights Include:
Research and Development, R&D, Safety and Pharmacovigilance
FEATURING PRESENTATIONS & CASE STUDIES FROM: |
|
|
|
CHINA  |
 |
Dr. Victoria Elegant
Vice-President, Medical & Regulatory Affairs , Asia-Pacific, Baxter Healthcare |
 |
Hanlim Moon
Oncology Medical Director, China and Asia, R&D China and Global Oncology, GSK |
 |
Dr. Tadaaki Taniguchi
Executive Director and Strategic Officer, China Development, Emerging Markets R&D, MSD (Shanghai) Pharmaceuticals Consultancy |
| |
|
JAPAN  |
 |
Shinichi Nishiuma
Senior Medical Advisor/ Lead Physician &
Senior Manager, Surveillance & Epidemiology
Global Patient Safety Japan, Lilly Research
Laboratories, Eli Lilly Japan K.K. & Vice Chairperson, The Japanese Association of
Pharmaceutical Medicine (JAPhMed) |
 |
Dr. Koichi Miyazaki
Associate Director, Clinical Development
Group, Asia Development Department, Daiichi Sankyo |
|
- Ensuring the Commercial Success of
Your Drugs
• Marketing strategies using real-world
data
• Label expansions
• Planning optimal post-marketing studies
- Building Optimal Observational
Research & Patient Registries
- Overcoming Operational Challenges
in Late Phase Trials
• Multi – Country, Multi – Center Studies
• Site Management
• Patient Recruitment & Retention
- Late Phase and Post Marketing
Requirements in Asia
- Late Phase Development and Safety
Surveillance Strategies
|
|
| 5 REASONS WHY
YOU MUST ATTEND |
- Gain insights into developing late
stage strategies for Asian region
- Discover what it takes to optimise
commercial benefits from late phase
studies
- Gain insights into designing optimal
non-interventional studies and patient
registries by accessing real-life
experiences
- Learn about the best practices in
operations and collection of quality
data in large-scale clinical studies
- Identify new trends in project
management and patient
recruitment/retention across the
region
|
|
|
|
| Other Languages |
 |
|
|
|
